Clinical Trial Update: Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating a theranostic tool used during erlotinib treatment for patients with metastatic or recurrent non-small cell lung cancer lac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: University Hospital, Angers | Conditions: Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent, No EGFR Activating Mutation | Phase 2 | Status: UNKNOWN